Clinical trial
Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial
NCT01611077 is registered in ClinicalTrials.gov with Institut für Pharmakologie und Präventive Medizin as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial
- Lead sponsor
- Institut für Pharmakologie und Präventive Medizin
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- January 31, 2013
- Enrollment
- 88 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.